Virpax Pharmaceuticals, Inc.
VRPXDelisted Jul 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted on Jul 21, 2025; its insiders filed their last Form 4 on Jul 10, 2024; 7 institutions reported holding it in 13F filings for Q1 2025, worth $34.9K in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in Virpax Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
VRPX is no longer listed, so this page shows Q1 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 7
- −5 vs. Q4 2024
- Shares held
- 29.1K
- −97.1K (−76.9%) vs. Q4 2024
- Total value
- $34.9K
- −$11.8K (−25.3%) vs. Q4 2024
- New holders
- 1
- 0 more added
- Sold out
- 6
- 6 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 7 | $34.9K |
| Q4 2024 | 12 | $46.7K |
| Q3 2024 | 9 | $66.8K |
| Q2 2024 | 8 | $12.6K |
| Q1 2024 | 6 | $6.44K |
| Q4 2023 | 18 | $120.5K |
| Q3 2023 | 13 | $493.4K |
| Q2 2023 | 14 | $827.7K |
| Q1 2023 | 17 | $873.8K |
| Q4 2022 | 21 | $973.0K |
| Q3 2022 | 16 | $2.17M |
| Q2 2022 | 16 | $3.13M |
| Q1 2022 | 16 | $3.29M |
| Q4 2021 | 18 | $7.67M |
| Q3 2021 | 13 | $11.4M |
| Q2 2021 | 7 | $1.12M |
| Q1 2021 | 5 | $1.29M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Virpax Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vermillion Wealth Management, Inc. | 4 | $5 | 0.00% | −96−96.0% | Reduced |
| Bank of America Corp | 5 | $6 | 0.00% | −60−92.3% | Reduced |
| Advisor Group Holdings, Inc. | 9 | $10 | 0.00% | −231−96.3% | Reduced |
| SBI Securities Co., Ltd. | 108 | $130 | 0.00% | −492−82.0% | Reduced |
| UBS Group AG | 2,000 | $2.40K | 0.00% | −11,100−84.7% | Reduced |
| Tower Research Capital LLC (TRC) | 4,897 | $5.88K | 0.00% | −2,857−36.8% | Reduced |
| Millennium Management LLC | 22,075 | $26.5K | 0.00% | +22,075 | New |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −41,899−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −25,368−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −23,657−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −12,905−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −499−100.0% | Sold out |
| Hantz Financial Services, Inc. | 0 | $0 | 0.00% | −10−100.0% | Sold out |